Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Diatos
company
About
Diatos is a biopharmaceutical company developing innovative therapies for unmet medical needs in cancer.
- 11 - 50
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $12.80M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 1999
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA.Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$12.80M
Diatos has raised a total of
$12.80M
in funding over 2 rounds. Their latest funding was raised on
Jul 3, 2007 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 3, 2007 | Series D | $12.80M | 4 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
4
Diatos is funded by 4 investors.
Biotech Fund Flanders
and NIF SMBC Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Biotech Fund Flanders
|
— | Series D |
NIF SMBC Ventures
|
— | Series D |
Sopartec
|
— | Series D |
Credit Agricole Entreprises
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
